Cardiac Troponin Elevation and Outcome after XXXX : A Systematic Review and Meta-analysis.

@entity1 @entity2806 @entity510 @entity299 @entity204
BACKGROUND: @entity299 frequently occur after @entity510 ( @entity510 ). Cardiac troponin (cTn) is a preferred biomarker for the diagnosis of @entity299 , and the clinical significance of cTn elevation after @entity510 remains controversial. This meta-analysis was performed to assess the association between cTn elevation and @entity1 outcomes, including delayed @entity2806 (DCI), poor outcome ( @entity204 or dependency), and @entity204 in @entity510 @entity1 . METHODS: PubMed, Embase, and the Cochrane Library were searched for observational studies reporting an association between cTn elevation and outcome after @entity510 that were published before December 31, 2014. We extracted data regarding @entity1 characteristics, cTn elevation, and outcome measurements (DCI, poor outcome, or @entity204 ). Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS: Twelve studies involving 2214 @entity1 were included in data analysis. Elevation of cTn was observed in 30% of the @entity1 . The cTn elevation was associated with an increased risk of DCI (RR, 1.48; 95% CI, 1.23-1.79), poor outcome (RR, 1.91; 95% CI, 1.51-2.40), and @entity204 (RR, 2.53; 95% CI, 2.04-3.12). At the 3- and 12-  month follow-ups, cTn elevation was associated with higher rates of DCI (RR, 1.51; 95% CI, 1.11-2.07), poor outcome (RR, 1.91; 95% CI, 1.51-2.40), and @entity204 (RR, 2.78; 95% CI, 1.80-4.29). At in-hospital follow-ups, cTn elevation was also associated with the higher rate of @entity204 (RR, 2.33; 95% CI, 1.76-3.07). CONCLUSIONS: cTn elevation in @entity510 @entity1 is associated with an increased risk of DCI, poor outcome, and @entity204 after @entity510 .
